Advertisements
Advertisements

Manufacturing of highly potent compounds is a laborious procedure, plagued with various difficulties, including high capital investment, extensive operational expertise, as well as access to advanced infrastructure and technologies.

Advertisements

As a result, outsourcing has become a preferred business model in this domain, providing increased flexibility, reduced costs and timely launch of drugs. Further, to keep up with the evolving client requirements, several contract manufacturing organizations have upgraded their existing capabilities / facilities.

The USD 40 billion (by 2035) financial opportunity within the HPAPI and cytotoxic drug manufacturing market has been analyzed across the following segments:

  • Type of Product
  • Highly Potent Active Pharmaceutical Ingredient
  • Highly Potent Finished Dosage Form
  • Company Size
  • Small
  • Mid-sized
  • Large
  • Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Type of Molecule
  • Small Molecules
  • Biologics
  • Type of Highly Potent Finished Dosage Form
  • Injectables
  • Oral Solids
  • Creams
  • Others
  • Key Geographical Regions 
  • North America (US, Canada and Mexico)
  • Europe (UK, Italy, Germany, France, Spain and Rest of Europe)
  • Asia-Pacific (China, India and Rest of Asia-Pacific)
  • Rest of the World  

The HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022 – 2035 report features the following companies, which we identified to be key players in this domain:

  • AbbVie
  • Abzena
  • Aenova
  • Cambrex
  • CARBOGEN AMCIS
  • Catalent
  • Hovione
  • Intas Pharmaceuticals
  • Lonza
  • Pfizer CentreOne
  • Piramal Pharma Solutions
  • Scinopharm
  • STA Pharmaceutical (a WuXi AppTec company)
  • Syngene
  • Teva API

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Competitiveness Analysis

6. Company Profiles: HPAPI and Cytotoxic Drug Manufacturers in North

    America

7. Company Profiles: HPAPI And Cytotoxic Drug Manufacturers in Europe

8. Company Profiles: HPAPI and Cytotoxic Drug Manufacturers in Asia-

    Pacific and Rest of the World

9. Partnerships and Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Regional Capability Assessment Analysis

13. Make Versus Buy Decision Making Framework

14. Market Sizing and Opportunity Analysis

15. Swot Analysis

16. Case-in-point: Contract Manufacturing Of Antibody Drug Conjugates

17. Concluding Remarks

18. Executive Insights

19. Appendix 1: Tabulated Data

20. Appendix 2: List of Companies and Organizations

To view more details on this report, click on the link:

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

You may also be interested in the following titles:

Cell Therapy Manufacturing Market

Global TCR Therapy Market

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here

20 − five =